Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area

• Published in: Therapeutic advances in psychopharmacology 2023-01, Vol.13, p.20451253231211574
• Main Authors: Mohr, Grimur Høgnason, Barcella, Carlo Alberto, Grand, Mia Klinten, Kriegbaum, Margit, Siersma, Volkert, Hahn, Margaret K., Agarwal, Sri Mahavir, Bakkedal, Catrine, Baandrup, Lone, Knop, Filip Krag, Andersen, Christen Lykkegaard, Ebdrup, Bjørn Hylsebeck
• Format: Article
• Language: English
• Subjects: Drug therapy; Ischemia; Lipids; Mental disorders; Metabolic disorders
• ISSN: 2045-1253; 2045-1261
• DOI: 10.1177/20451253231211574

Background: Severe mental illness (SMI) is associated with increased cardiovascular risk. Dyslipidaemia is a potentially modifiable risk factor, which may be inadequately managed in patients with SMI. Objectives: To assess management of dyslipidaemia in patients with SMI versus healthy controls (HCs) in 2005 and 2015. Design and methods: Using Danish registers, we identified adult patients with SMI in the Greater Copenhagen Area (schizophrenia spectrum disorders or bipolar disorder) with ⩾1 general practitioner contact in the year before 2005 and 2015, respectively, and HCs without SMI matched on age and gender (1:5). Outcomes were lipid-profile measurements, presence of dyslipidaemia and redemption of lipid-lowering pharmacotherapy. Differences in outcomes between patients with SMI and controls were measured with multivariable logistic regression. Results: We identified 7217 patients with SMI in 2005 and 9939 in 2015. After 10 years, patients went from having lower odds of lipid measurements to having higher odds of lipid measurements compared with HCs [odds ratio (OR)2005 0.70 (99% confidence interval (CI) 0.63–0.78) versus OR2015 1.34 (99% CI 1.24–1.44); p2005versus2015